139 related articles for article (PubMed ID: 31365178)
1. Platelet count increases after viral elimination in chronic HCV, independent of the presence or absence of cirrhosis.
Sayyar M; Saidi M; Zapatka S; Deng Y; Ciarleglio M; Garcia-Tsao G
Liver Int; 2019 Nov; 39(11):2061-2065. PubMed ID: 31365178
[TBL] [Abstract][Full Text] [Related]
2. Platelet Count Improvement after Chronic Hepatitis C Treatment among Cirrhotic Patients Who Achieved Sustained Virological Response: Realworld Results from 2186 Patients in Egypt.
Badawi R; Soliman S; Aboali L; Elkadeem M; Elfert A; Elguindy AMA; Ullah MS; Abd-Elsalam S
Endocr Metab Immune Disord Drug Targets; 2021; 21(7):1300-1305. PubMed ID: 32940191
[TBL] [Abstract][Full Text] [Related]
3. Improvement of platelets after SVR among patients with chronic HCV infection and advanced hepatic fibrosis.
van der Meer AJ; Maan R; Veldt BJ; Feld JJ; Wedemeyer H; Dufour JF; Lammert F; Duarte-Rojo A; Manns MP; Zeuzem S; Hofmann WP; de Knegt RJ; Hansen BE; Janssen HL
J Gastroenterol Hepatol; 2016 Jun; 31(6):1168-76. PubMed ID: 26647353
[TBL] [Abstract][Full Text] [Related]
4. Interference of hepatitis B virus dual infection in platelet count recovery in chronic hepatitis C patients with curative antiviral therapy.
Huang CF; Yeh ML; Huang CI; Lin ZY; Chen SC; Dai CY; Huang JF; Chuang WL; Yu ML
J Gastroenterol Hepatol; 2018 May; 33(5):1108-1114. PubMed ID: 29023927
[TBL] [Abstract][Full Text] [Related]
5. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy.
Afdhal NH; Dusheiko GM; Giannini EG; Chen PJ; Han KH; Mohsin A; Rodriguez-Torres M; Rugina S; Bakulin I; Lawitz E; Shiffman ML; Tayyab GU; Poordad F; Kamel YM; Brainsky A; Geib J; Vasey SY; Patwardhan R; Campbell FM; Theodore D
Gastroenterology; 2014 Feb; 146(2):442-52.e1. PubMed ID: 24126097
[TBL] [Abstract][Full Text] [Related]
6. Aging impairs fibrosis-4 index after sustained virologic response by direct-acting antivirals in chronic hepatitis C infection.
Nakajima T; Karino Y; Hige S; Suii H; Tatsumi R; Yamaguchi M; Arakawa T; Kuwata Y; Toyota J
Ann Hepatol; 2022; 27(1):100566. PubMed ID: 34688887
[TBL] [Abstract][Full Text] [Related]
7. Effect of direct-acting antivirals on platelet-associated immunoglobulin G and thrombocytopenia in hepatitis C virus-related chronic liver disease.
Honma Y; Shibata M; Hayashi T; Kusanaga M; Ogino N; Minami S; Kumei S; Oe S; Miyagawa K; Senju M; Matsuoka H; Watanabe T; Hiura M; Abe S; Harada M
Liver Int; 2019 Sep; 39(9):1641-1651. PubMed ID: 31009141
[TBL] [Abstract][Full Text] [Related]
8. Factors Associated with Significant Platelet Count Improvement in Thrombocytopenic Chronic Hepatitis C Patients Receiving Direct-Acting Antivirals.
Chen YC; Chang TS; Chen CH; Cheng PN; Lo CC; Mo LR; Chen CT; Huang CF; Kuo HT; Huang YH; Tai CM; Peng CY; Bair MJ; Yeh ML; Lin CL; Lin CY; Lee PL; Chong LW; Hung CH; Huang JF; Yang CC; Hu JT; Lin CW; Wang CC; Su WW; Hsieh TY; Lin CL; Tsai WL; Lee TH; Chen GY; Wang SJ; Chang CC; Yang SS; Wu WC; Huang CS; Hsiung CK; Kao CN; Tsai PC; Liu CH; Lee MH; Dai CY; Kao JH; Chuang WL; Lin HC; Chen CY; Tseng KC; Yu ML; On Behalf Of Tacr Investigators
Viruses; 2022 Feb; 14(2):. PubMed ID: 35215926
[TBL] [Abstract][Full Text] [Related]
9. Predictors of functional benefit of hepatitis C therapy in a 'real-life' cohort.
Steinebrunner N; Stein K; Sandig C; Bruckner T; Stremmel W; Pathil A
World J Gastroenterol; 2018 Feb; 24(7):852-861. PubMed ID: 29467555
[TBL] [Abstract][Full Text] [Related]
10. Management of HCV-related decompensated cirrhosis with direct-acting antiviral agents: who should be treated?
Hanafy AS; Bassiony MA; Basha MAA
Hepatol Int; 2019 Mar; 13(2):165-172. PubMed ID: 30758786
[TBL] [Abstract][Full Text] [Related]
11. Mean Platelet Volume, Red Cell Distribution Width to Platelet Count Ratio, Globulin Platelet Index, and 16 Other Indirect Noninvasive Fibrosis Scores: How Much Do Routine Blood Tests Tell About Liver Fibrosis in Chronic Hepatitis C?
Thandassery RB; Al Kaabi S; Soofi ME; Mohiuddin SA; John AK; Al Mohannadi M; Al Ejji K; Yakoob R; Derbala MF; Wani H; Sharma M; Al Dweik N; Butt MT; Kamel YM; Sultan K; Pasic F; Singh R
J Clin Gastroenterol; 2016 Jul; 50(6):518-23. PubMed ID: 26974762
[TBL] [Abstract][Full Text] [Related]
12. α-fetoprotein levels after interferon therapy predict regression of liver fibrosis in patients with sustained virological response.
Tachi Y; Hirai T; Ishizu Y; Honda T; Kuzuya T; Hayashi K; Ishigami M; Goto H
J Gastroenterol Hepatol; 2016 May; 31(5):1001-8. PubMed ID: 27123974
[TBL] [Abstract][Full Text] [Related]
13. Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy.
Thabut D; Bureau C; Layese R; Bourcier V; Hammouche M; Cagnot C; Marcellin P; Guyader D; Pol S; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Goria O; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle-Bladou C; Dao T; Pilette C; Silvain C; Christidis C; Capron D; Bernard-Chabert B; Hillaire S; Di Martino V; Sutton A; Audureau E; Roudot-Thoraval F; Nahon P;
Gastroenterology; 2019 Mar; 156(4):997-1009.e5. PubMed ID: 30768988
[TBL] [Abstract][Full Text] [Related]
14. Impact of sustained virologic response on short-term clinical outcomes in hepatitis C-related cirrhosis.
Bashir MH; Fazili J; Madhoun MF; Kanagala R; Chen S; Nusrat S
Eur J Gastroenterol Hepatol; 2018 Mar; 30(3):296-301. PubMed ID: 29200006
[TBL] [Abstract][Full Text] [Related]
15. Histopathology and the predominantly progressive, indeterminate and predominately regressive score in hepatitis C virus patients after direct-acting antivirals therapy.
Huang R; Rao HY; Yang M; Gao YH; Wang J; Jin Q; Ma DL; Wei L
World J Gastroenterol; 2021 Feb; 27(5):404-415. PubMed ID: 33584072
[TBL] [Abstract][Full Text] [Related]
16. Effects of HCV Clearance with Direct-Acting Antivirals (DAAs) on Liver Stiffness, Liver Fibrosis Stage and Metabolic/Cellular Parameters.
Ferreira J; Bicho M; Serejo F
Viruses; 2024 Feb; 16(3):. PubMed ID: 38543737
[TBL] [Abstract][Full Text] [Related]
17. Liver stiffness measurements and FIB-4 are predictors of response to sofosbuvir-based treatment regimens in 7256 chronic HCV patients.
Abdel Alem S; Elsharkawy A; El Akel W; Abdelaziz AO; Salama RM; El-Sayed MH; El Kassas M; Anees M; Shedeed M; Abdelsalam F; Ziada DH; El Shazly Y; El-Serafy M; Waked I; Esmat G; Doss W
Expert Rev Gastroenterol Hepatol; 2019 Oct; 13(10):1009-1016. PubMed ID: 31418303
[No Abstract] [Full Text] [Related]
18. Rapid platelet count improvement in chronic hepatitis C patients with thrombocytopenia receiving direct-acting antiviral agents.
Chen YC; Tseng CW; Tseng KC
Medicine (Baltimore); 2020 May; 99(19):e20156. PubMed ID: 32384505
[TBL] [Abstract][Full Text] [Related]
19. Hematologic indices improve with eradication of HCV in patients with cirrhosis and predict decompensation.
Karagozian R; Grace ND; Qamar AA
Acta Gastroenterol Belg; 2014 Dec; 77(4):425-32. PubMed ID: 25682633
[TBL] [Abstract][Full Text] [Related]
20. Real life application of FIB-4 & APRI during mass treatment of HCV genotype 4 with directly acting anti-viral agents in Egyptian patients, an observational study.
Said M; Soliman Z; Daebes H; M El-Nahaas S; El-Serafy M
Expert Rev Gastroenterol Hepatol; 2019 Dec; 13(12):1189-1195. PubMed ID: 31702417
[No Abstract] [Full Text] [Related]
[Next] [New Search]
